| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PHA-793887 | CTRPv2 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | Gefitinib | FIMM | pan-cancer | AAC | 0.092 | 0.6 |
| mRNA | Bortezomib | FIMM | pan-cancer | AAC | -0.085 | 0.6 |
| mRNA | THZ-2-49 | GDSC1000 | pan-cancer | AAC | -0.016 | 0.6 |
| mRNA | PRIMA-1-Met | CTRPv2 | pan-cancer | AAC | -0.029 | 0.6 |
| mRNA | selumetinib:piperlongumine (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.019 | 0.6 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | LBW242 | CCLE | pan-cancer | AAC | -0.026 | 0.6 |
| mRNA | BRD-K33514849 | CTRPv2 | pan-cancer | AAC | 0.072 | 0.6 |
| mRNA | GSK1120212 | CTRPv2 | pan-cancer | AAC | 0.026 | 0.6 |